Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study

Simple item page
dc.contributor.authorWang, Minggui
dc.contributor.authorEarley, Michelle
dc.contributor.authorChen, Liang
dc.contributor.authorHanson, Blake M.
dc.contributor.authorYu, Yunsong
dc.contributor.authorLiu, Zhengyin
dc.contributor.authorSalcedo, Soraya
dc.contributor.authorCober, Eric
dc.contributor.authorLi, Lanjuan
dc.contributor.authorKanj, Souha S.
dc.contributor.authorGao, Hainv
dc.contributor.authorMunita, José
dc.contributor.authorOrdoñez, Karen
dc.contributor.authorWeston, Greg
dc.contributor.authorSatlin, Michael J.
dc.contributor.authorValderrama-Beltrán, Sandra L.
dc.contributor.authorMarimuthu, Kalisvar
dc.contributor.authorStryjewski, Martin E.
dc.contributor.authorKomarow, Lauren
dc.contributor.authorLuterbach, Courtney
dc.contributor.authorMarshall, Steve H.
dc.contributor.authorRudin, Susan D.
dc.contributor.authorManca, Claudia
dc.contributor.authorPaterson, David L.
dc.contributor.authorDoi, Yohei
dc.contributor.authorPatel, Robin
dc.contributor.authorKreiswirth, Barry N.
dc.contributor.authorBonomo, Robert A.
dc.contributor.authorChambers, Henry F.
dc.contributor.authorFowler, Jr. Vance G.
dc.contributor.authorArias, Cesar A.
dc.contributor.authorDuin, David van
dc.contributor.authorMulti-Drug Resistant Organism Network Investigators
dc.date.accessioned
dc.date.available2022-01-06T15:09:39Z
dc.date.issued2021
dc.description.abstractBackground: Carbapenem-resistant Enterobacterales (CRE) are a global threat. We aimed to describe the clinical and molecular characteristics of Centers for Disease Control and Prevention (CDC)-defined CRE in the USA. Methods: CRACKLE-2 is a prospective, multicentre, cohort study. Patients hospitalised in 49 US hospitals, with clinical cultures positive for CDC-defined CRE between April 30, 2016, and Aug 31, 2017, were included. There was no age exclusion. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture. Clinical data and bacteria were collected, and whole genome sequencing was done. This trial is registered with ClinicalTrials.gov, number NCT03646227. Findings: 1040 patients with unique isolates were included, 449 (43%) with infection and 591 (57%) with colonisation. The CDC-defined CRE admission rate was 57 per 100 000 admissions (95% CI 45-71). Three subsets of CDC-defined CRE were identified: carbapenemase-producing Enterobacterales (618 [59%] of 1040), non-carbapenemase-producing Enterobacterales (194 [19%]), and unconfirmed CRE (228 [22%]; initially reported as CRE, but susceptible to carbapenems in two central laboratories). Klebsiella pneumoniae carbapenemase-producing clonal group 258 K pneumoniae was the most common carbapenemase-producing Enterobacterales. In 449 patients with CDC-defined CRE infections, DOOR outcomes were not significantly different in patients with carbapenemase-producing Enterobacterales, non-carbapenemase-producing Enterobacterales, and unconfirmed CRE. At 30 days 107 (24%, 95% CI 20-28) of these patients had died. Interpretation: Among patients with CDC-defined CRE, similar outcomes were observed among three subgroups, including the novel unconfirmed CRE group. CDC-defined CRE represent diverse bacteria, whose spread might not respond to interventions directed to carbapenemase-producing Enterobacterales. Funding: National Institutes of Health.es
dc.description.versionVersión publicada
dc.identifier.citationWang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, Salcedo S, Cober E, Li L, Kanj SS, Gao H, Munita JM, Ordoñez K, Weston G, Satlin MJ, Valderrama-Beltrán SL, Marimuthu K, Stryjewski ME, Komarow L, Luterbach C, Marshall SH, Rudin SD, Manca C, Paterson DL, Reyes J, Villegas MV, Evans S, Hill C, Arias R, Baum K, Fries BC, Doi Y, Patel R, Kreiswirth BN, Bonomo RA, Chambers HF, Fowler VG Jr, Arias CA, van Duin D; Multi-Drug Resistant Organism Network Investigators. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect Dis. 2021 Nov 9:S1473-3099(21)00399-6. doi: 10.1016/S1473-3099(21)00399-6es
dc.identifier.urihttp://doi.org/10.1016/S1473-3099(21)00399-6es
dc.identifier.urihttp://hdl.handle.net/11447/5357
dc.language.isoenes
dc.subjectCarbapenem-Resistant Enterobacteriaceae* / drug effectses
dc.titleClinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort studyes
dc.typeArticlees
dcterms.sourceThe Lancet Infectious Diseaseses

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
CRACKLE MDRO_LancetID_2021 (1).pdf
Size:
1.42 MB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services